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Abstract
OBJECTIVE: To observe the curative effect of Huq-
ian Wan on liver and kidney-Yin deficiency knee os-
teoarthritis (KOA).
METHODS: One hundred patients were randomly
divided into a treatment (50 patients) and control
group (50 patients). In the treatment group, pa-
tients orally took the Chinese medicine Huqian
Wan. Control group patients orally took Votalin, 75
mg, once a day, for 8 weeks. The visual analog scale
(VAS), Western Ontario and McMaster University Os-
teoarthritis Index (WOMAC), and Medical Out-
comes Study Short Form 36-Item Health Survey (SF
36) were used to evaluate the curative effect before
treatment and after 8 and 16 weeks of treatment.
RESULTS: VAS and WOMAC scores significantly de-
creased and SF 36 scores significantly increased af-
ter treatment in both groups compared with be-
fore treatment (P < 0.05). There were significant dif-
ferences in VAS, WOMAC, and SF 36 score changes
between the two groups at week 16 (P < 0.05).
There was a significant increase in VAS andWOMAC
scores in the control groups (P < 0.05) between
weeks 8 and 16, but no significant difference was
found in the treatment group (P > 0.05).
CONCLUSION: Huqian Wan could effectively im-
prove the clinical symptoms and quality of life in
patients with KOA. It could also have a better and
longer lasting curative effect without obvious ad-
verse events compared with Votalin.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Knee osteoarthritis (KOA) is a common chronic and
degenerative disease and costly public health problem.1
The disease usually results in pain, declined function,
and reduced quality of life (QOL).2,3 The prevalence of
KOA is high, with approximately 13% of women and
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10% of men over 60 years old suffering from symptom-
atic KOA.4 The etiology and pathogenesis of KOA is
not completely clear, and few effective Western medi-
cine treatments are available.5 Chinese medicine has
been used for healthcare for thousands of years in Chi-
na. In recent years, the use of traditional Chinese medi-
cine (TCM) for the management of KOA has in-
creased substantially.6,7 Therefore, it is necessary to ex-
plore effectiveness of TCM prescriptions used for KOA.
In terms of TCM, KOA is defined as Gu Bi (bone
rheumatism) and Gu Wei (atrophic debility of bones).
According to the guiding principles behind the clinical
study of new TCM drugs,8 KOA is classified into three
TCM patterns: liver-Yin deficiency, kidney-Yin defi-
ciency, and stasis of the channels. In clinical practice,
many KOA patients present with liver-Yin deficiency
and kidney-Yin deficiency patterns. We aimed to con-
duct a clinical study to investigate the effect of Huqian
Wan on liver-Yin and kidney-Yin deficiency in patients
with KOA.
METHODS
Demographics and characteristics of participants
One hundred patients with KOA were recruited as out-
patients in the First Affiliated Hospital of Zhejiang
Chinese Medical University from October 2012 to Oc-
tober 2013. Using computer randomization, patients
were assigned to a treatment (n = 50) or control group
(n = 50). In the treatment group, there were 22 males
and 28 females aged (59 ± 6) years on average, with an
average illness course of (22 ± 6) months. There were
14 cases of X-ray gradeⅠ, 27 cases of gradeⅡ, and 9
cases of grade Ⅲ. In the control group there were 21
males and 29 females aged (59 ± 7) years on average,
with an average illness course of (22 ± 7) months.
There were 12 cases of X-ray grade Ⅰ, 28 cases of
gradeⅡ, and 10 cases of gradeⅢ. There was no statis-
tical difference in age, sex, X-ray grading, or illness
course between the two groups (P > 0.05, Table 1).
This study was approved by the Ethical Committee of
Zhejiang Chinese Medical University, and all subjects
signed informed consent forms before treatment.
Diagnostic criteria
The diagnosis criteria for KOA were based on the
American College of Rheumatology (ACR) criteria.9
The criteria for the patterns of liver-Yin deficiency
and kidney-Yin deficiency were based on the Guid-
ance Principle of Clinical Study on New Drug of Tra-
ditional Chinese Medicine.8 X-ray grading of KOA
was classified according to the Kellgren-Lawrence cri-
teria.10
Inclusion criteria
We included the following: (a) patients of either sex,
aged 40-75 years; (b) patients fulfilling the KOA diag-
nostic criteria; (c) patients with pain in one or both
knees during the previous 3 months or longer; (d) pa-
tients with > 40 mm rating on the VAS; (e) patients
with a Kellgren-Lawrence X-ray grade from Ⅰ to Ⅲ
within 6 months; and (f ) patients who signed in-
formed consent forms.
Exclusion criteria
The following were excluded: (a) patients with signifi-
cant trauma or surgery on the knee(s) within past 6
months; (b) patients with rheumatoid, psoriatic arthri-
tis, or lupus; (c) patients with cancer of the knee; (d)
patients with allergic history; (e) patients with serious
organic disease (such as serious heart, kidney, liver, and
hematological diseases); (f ) patients with active peptic
ulcer or hemorrhage; (g) pregnant and lactating wom-
en; (h) patients with nervous system and mental diseas-
es; (i) patients that could not cease other treatments
that might influence the observation of indexes in this
study.
Treatments
Participants in the treatment group orally took Chi-
nese medicine, twice daily for 2 months. The treat-
ment recipe was composed of: Huangbai (Cortex Phel-
lodendri Amurensis) 12 g, Zhimu (Rhizoma Anemarrh-
enae) 9 g, Guijia (Carapax et Plastrum Testudinis) 10 g,
Shudihuang (Radix Rehmanniae Praeparata) 10 g,
Baishao (Radix Paeoniae Alba) 10 g, Suoyang (Herba
Cynomorii Songarici) 9 g, Niuxi (Radix Achyranthis Bi-
dentatae) 9 g, Duzhong (Cortex Eucommiae) 9 g,
Danggui (Radix Angelicae Sinensis) 9 g, Chenpi (Peri-
carpium Citri Reticulatae) 6 g, and Ganjiang (Rhi-
zoma Zingiberis) 6 g. All herbs were purchased from
Hangzhou Huadong Pharmaceutical Co., Ltd. (Hang-
zhou, China). Patients in the control group orally
took Votalin (produced by Beijing Nuohua Pharma-
ceutical Co., Ltd., Beijing, China), 75 mg once a day,
for 2 months.
Group
Treatment
Control
n
50
50
Gender
Male
22
21
Female
28
29
Age
(years)
59±6
59±7
X-ray grading
GradeⅠ
14
12
GradeⅡ
27
28
GradeⅢ
9
10
Illness course (months)
22±6
22±7
Table 1 Comparison of patient condition between groups ( xˉ ± s)
Notes: treatment group was given Chinese medicine orally, twice a day, for 2 months. Control group was given Votalin orally, 75 mg, once
a day, for 2 months.
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Outcome measurement
The primary outcome measurements were the Western
Ontario and McMaster University Osteoarthritis Index
(WOMAC)11 and VAS score, which were measured be-
fore treatment (week 0), immediately after treatment
(week 8), and at a 2 month follow-up (week 16). The
WOMAC is composed of 24 questions: pain (5 items),
stiffness (2 items), and physical functioning (17 items).
Individual questions are assigned a score of between 0
(none) to 4 (extreme) and summed to form a score
ranging from 0 (best) to 96 (worst). Higher total scores
indicate a more severe status.12,13 VAS is the most com-
mon method used in pain research.14 The VAS consists
of a 100 mm long horizontal line with two anchor
points of "no pain" and "worst pain". The patient is
asked to put a mark across the line at the point that
best describes their pain level, and the value is noted.
The secondary outcome measurement was the Medical
Outcomes Study Short Form 36-Item Health Survey
(SF 36),15 which was evaluated before treatment and at
week 16. The SF 36 questionnaire is used as a standard
international measurement of quality of life.16 It con-
tains nine aspects of health related quality of life: physi-
cal functioning, physical role, bodily pain, general
health, vitality, social functioning, emotional role, men-
tal health, and health transitions. Higher scores in this
questionnaire imply better patient status.
Statistical analysis
SPSS 17.0 statistical software package (IBM, New
York, NY, USA) was used to analyze data. Variables are
expressed as mean ± standard deviation ( xˉ ± s). T-tests
were performed for differences between groups. Statisti-
cal significance was taken at P < 0.05.
RESULTS
VAS Score
As shown in Table 2, there was no significant differ-
ence in VAS scores between the two groups before
treatment (P = 0.732, P > 0.05). The VAS score at each
time point after treatment were significantly lower
compared with those before treatment in both study
groups (P < 0.05). No significant difference was found
between the two groups at week 8 (P = 0.542, P >
0.05). However, the VAS score in the control group
was significantly higher than that in the treatment
group at week 16 (P = 0.001, P < 0.05). There was a
significant increase in the control group VAS score (P <
0.0001) from week 8 to 16. However, no significant
difference was observed in the treatment group from
week 8 to 16 (P = 0.059, P > 0.05).
WOMAC Scores
There were no significant differences in WOMAC
scores between the two groups before treatment (P >
0.05). WOMAC scores at each time point after treat-
ment significantly decreased from before to after treat-
ment in both groups (P < 0.05). The pain score was
not significantly different between the two groups at
week 8 (P > 0.05). However, the pain score in the con-
trol group was significantly higher than that in the
treatment group at week 16 (P < 0.05). The scores for
stiffness and physical function and the total scores in
the control group were significantly higher than those
in the treatment group (P < 0.05) at each time point af-
ter treatment. There was a significant increase in all
subcategories of the WOMAC score in the control
group (P < 0.05) from week 8 to 16. However, no sig-
nificant difference was observed in the treatment group
(Table 3).
SF 36 scores
There were no differences in the various indices of SF
36 score between the two groups before treatment (P >
0.05). The indices of SF 36 score were significantly
higher in both groups (P < 0.05) at week 16 compared
with before treatment. There were significant differenc-
es (P < 0.05) in physical functioning, physical role,
bodily pain, general health, vitality, and social function-
ing scores at week 16 between the two groups, and the
scores in the treatment group were higher than those in
the control group (Figure 1).
Adverse events
No adverse events were reported in the treatment
group during the experiment. In the control group, no
serious adverse events were reported. The most com-
mon minor adverse events were gastrointestinal discom-
fort in the control group. No patients withdrew from
the study.
DISCUSSION
KOA is defined as Gu Bi (bone rheumatism) and Gu
Wei (atrophic debility of bones) in TCM. TCM theo-
rizes that the kidney stores essence and governs the
growth and development of bone, and the liver stores
blood and reinforces tendons. Therefore, arthritis is
closely related to the kidney and liver. TCM further
theorizes that bone metabolism depends on abundance
Group
Treatment
Control
Before reatment
5.5±0.9
5.5±0.9
After treatment
Week 8
2.7±1.0a
2.6±1.0a
Week 16
2.9±1.3bc
3.8±1.2bd
Table 2 Changes in VAS score before and after treatment ( xˉ
± s)
Notes: treatment group received Chinese medicine twice a day
orally for 2 months. Control group received Votalin orally, 75 mg,
once a day, for 2 months. VAS: visual analog scale. aP < 0.05,
compared with the datum at week 0 in the same group; bP <
0.05, as compared with the datum at week 0 in the same group;
cP < 0.05, as compared with the datum in the control group;
dP < 0.05, as compared with the datum at week 8 in the same
group.
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of essence and marrow, which provide nutrition to the
bone. When a person ages, kidney Yin, essence, and
marrow gradually become insufficient, the bones are
deprived of nourishment, and the articular cartilage de-
generates, which and leads to osteoarthritis. If water
fails to constrain fire owing to Yin deficiency, there is a
disturbance caused by heat, which further burns the
body fluid and leads to blood stasis. Blood stasis blocks
meridians, causes pain, and makes the bone dystrophy
worse. Yin deficiency of the liver and kidney is the fun-
damental aspect of KOA, and excessive fire is also of-
ten present. Therefore, KOA should be treated by
nourishing Yin and clearing fire.
In the recipe for Huqian Wan, Huangbai (Cortex Phel-
lodendri Amurensis) clears heat and purges pathogenic
fire. Guijia (Carapax et Plastrum Testudinis) is capable
of nourishing Yin and subduing Yang, filling the mar-
row essence, and strengthening bone. Huangbai (Cor-
tex Phellodendri Amurensis) and Gui Ban are used in
large dosages as monarch drugs to greatly reinforce gen-
uine Yin and strengthen the water to control the fire,
which aims to treat the symptoms and root causes.
Shudihuang (Radix Rehmanniae Praeparata) can replen-
ish marrow and supplement essence, and Baishao (Ra-
dix Paeoniae Alba) nourishes blood and astringes Yin.
The cooperation of Shudihuang (Radix Rehmanniae
Praeparata) and Baishao (Radix Paeoniae Alba) with
Guijia (Carapax et Plastrum Testudinis) can strengthen
the Yin nourishing effect. Zhimu (Rhizoma Anemarrhe-
nae) can nourish Yin and clear heat, especially when
combined with Huangbai (Cortex Phellodendri Amuren-
sis). Shudihuang (Radix Rehmanniae Praeparata),
Baishao (Radix Paeoniae Alba), and Zhimu (Rhizoma
Anemarrhenae) are ministerial drugs. Niuxi (Radix
Achyranthis Bidentatae) and Duzhong (Cortex Eucommi-
ae) to replenish the kidney, tonify the liver, and
strengthen the waist and bones. Danggui (Radix Angeli-
cae Sinensis) tonifies blood and nourishes the liver.
Danggui (Radix Angelicae Sinensis) can not only help
Shudihuang (Radix Rehmanniae Praeparata) enrich
blood and promote blood circulation, but relieve
spasms to arrest pain when combined with Baishao
(Radix Paeoniae Alba). Suoyang (Herba Cynomorii Son-
garici) can tonify kidney Yang and replenish essence,
Table 3 Comparison of changes inWOMAC score before and after treatment ( xˉ ± s )
Notes: treatment group was given Chinese medicine twice a day, orally for 2 months. Control group was given Votalin orally, 75 mg, once
a day, for 2 months. WOMAC: the Western Ontario and McMaster University Osteoarthritis Index. aP < 0.05, as compared with the
datum at week 0 in the same group; bP < 0.05, as compared with the datum in the control group; cP < 0.05, as compared with the datum
at week 0 in the same group; dP < 0.05, as compared with the datum at week 8 in the same group.
Group
Treatment
Control
Pain
Stiffness
Physical function
Total score
Pain
Stiffness
Physical function
Total score
Before treatment
6.5±1.0
2.3±1.2
28.3±2.5
37.2±4.5
6.6±0.9
2.4±1.1
28.8±2.8
37.8±4.6
After treatment
Week 8
3.6±0.8a
1.3±0.7ab
15.4±2.9ab
21.0±4.2ab
3.5±0.9a
1.7±0.8a
18.1±2.2a
23.2±3.6a
Week 16
3.8±1.2bc
1.4±1.0bc
15.6±3.6bc
20.9±5.4bc
4.9±1.0cd
2.1±1.1cd
20.1±2.5cd
27.1±4.2cd
Figure 1 Comparisons of changes in SF 36 scores before and after treatment
1: physical functioning; 2: role physical; 3: bodily pain; 4: general health; 5: vitality; 6: social functioning; 7: role emotional; 8: men-
tal health. SF 36: medical outcomes study short form 36-item health survey. Treatment group was given Chinese medicine twice a
day, orally for 2 months. Control group was given Votalin orally, 75 mg, once a day, for 2 months. Week 0: before treatment; Week
16: week 16 after treatment. aP < 0.05, as compared with the datum in the same group at week 16; bP < 0.05, as compared with the
datum in the control group at week 16.
1 2 3 4 5 6 7 8
Treatment group week 0 Treatment group week 16 Control group week 16Control group week 0
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which implies "treating Yang for Yin." Chenpi (Pericar-
pium Citri Reticulatae) and Ganjiang (Rhizoma Zingib-
eris) invigorate the spleen and regulate stomach Qi.
These herbs act as adjuvant and guiding drugs. The
combination of all drugs can nourish Yin, purge fire,
and strengthen the muscles and bones.
The results of this study showed that the VAS and
WOMAC scores in both groups were significantly low-
er after treatment at each time point compared with
those before treatment. SF 36 scores were also signifi-
cantly higher after treatment. Each score indicated that
both treatment methods could significantly improve
the symptoms and quality of life of patients with KOA.
The pain score (including the VAS and WOMAC) was
not significantly different at week 8 between the
groups. However, the treatment group scores were sig-
nificantly higher than those in the control group at
week 16. This result indicates that the analgesic effects
of the two groups were similar at week 8, but the effica-
cy of the treatment group was superior to that of the
control group at 16 weeks. There was a significant in-
crease in all subcategories of the VAS and WOMAC
scores in the control group from weeks 8 to 16. Howev-
er, no significant difference was found in the treatment
group from weeks 8 to 16. The results preliminarily in-
dicate that the curative effect of the treatment group
lasted longer than that of control group. However, fur-
ther data and long-term follow-up are required to con-
firm the duration of effect. The SF 36 scores indicate
that the treatment group had a better curative effect at
improving physical functioning, physical role, bodily
pain, general health, vitality, and social functioning
compared with the control group.
In conclusion, compared with Votalin, Huqian Wan is
effective at improving symptoms and quality of life in
patients with KOA. Huqian Wan had a lasting curative
effect without obvious adverse events. Therefore, Huq-
ian Wan might be an alternative to the treatment of liv-
er and kidney-Yin deficiency in patients with KOA.
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